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Abstract
Introduction Loss of the cell-cycle inhibitory protein p27Kip1 is
associated with a poor prognosis in breast cancer. The
decrease in the levels of this protein is the result of increased
proteasome-dependent degradation, mediated and rate-limited
by its specific ubiquitin ligase subunits S-phase kinase protein 2
(Skp2) and cyclin-dependent kinase subunit 1 (Cks1). Skp2
was recently found to be overexpressed in breast cancers, but
the role of Cks1 in these cancers is unknown. The present study
was undertaken to examine the role of Cks1 expression in breast
cancer and its relation to p27Kip1 and Skp2 expression and to
tumor aggressiveness.
Methods The expressions of Cks1, Skp2, and p27Kip1 were
examined immunohistochemically on formalin-fixed, paraffin-
wax-embedded tissue sections from 50 patients with breast
cancer and by immunoblot analysis on breast cancer cell lines.
The relation between Cks1 levels and patients' clinical and
histological parameters were examined by Cox regression and
the Kaplan–Meier method.
Results The expression of Cks1 was strongly associated with
Skp2 expression (r = 0.477; P = 0.001) and inversely with
p27Kip1 (r = -0.726; P < 0.0001). Overexpression of Cks1 was
associated with loss of tumor differentiation, young age, lack of
expression of estrogen receptors and of progesterone
receptors, and decreased disease-free (P = 0.0007) and overall
(P = 0.041) survival. In addition, Cks1 and Skp2 expression
were increased by estradiol in estrogen-dependent cell lines but
were down-regulated by tamoxifen.
Conclusion These results suggest that Cks1 is involved in
p27Kip1 down-regulation and may have an important role in the
development of aggressive tumor behavior in breast cancer.
Introduction
The prognosis and clinical management of patients with breast
cancer are commonly determined by traditional clinicopatho-
logical factors such as tumor size and grade, lymph node sta-
tus, and the expression of receptors to estrogen (ERs) and to
progesterone (PRs) and of Her2/neu [1]. Nevertheless,
patients may have significantly different clinical outcomes
despite similar clinicopathological features. Some of these dif-
ferences may be attributed to alterations in the normal regula-
tion of the cell cycle that ultimately lead to aggressive tumor
behavior.
Among the various cell-cycle proteins, deregulation of p27Kip1
expression was found to have a particularly important role in
cancer [2]. Numerous studies have shown that down regula-
tion of p27Kip1, an inhibitor of cyclin-dependent kinases, is
associated with poor prognosis in many cancers, including
breast, colorectal, prostate, and lung carcinomas [3-8]. The
decrease in p27Kip1 levels in these cancers was found to result
from its rapid degradation by the ubiquitin–proteasome path-
way, rather than from decreased protein synthesis or gene
mutation [6,9,10].
Cks = cyclin kinase subunit; ER = estrogen receptor; PR = progesterone receptor; Skp = S-phase kinase protein; TBST = Tris-buffered saline and 
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The main rate-limiting regulator for p27Kip1 degradation was
identified as an SCF-type ubiquitin ligase complex that con-
tains S-phase kinase protein 2 (Skp2) as the specific sub-
strate-recognition subunit [11-13]. Skp2 specifically binds
p27Kip1 and targets it for degradation by the ubiquitin proteo-
lytic system. The important role of Skp2 in controlling p27Kip1
levels in some human cancers, including breast, prostate,
colorectal, and oral squamous cell carcinomas, was recently
emphasized [14-17]. Thus, increased expression of Skp2 in
these tumors was associated with low p27Kip1 levels, aggres-
sive tumor behavior, and poor overall survival.
More recently, the essential role of cyclin kinase subunit 1
(Cks1) in facilitating the ubiquitin-mediated proteolysis of
p27Kip1 through interaction with Skp2 was discovered [18,19].
Cks1 is a member of the highly conserved family of Cks/Suc1
(Schizosaccharomyces pombe cell-cycle regulatory protein)
proteins, which interact with Cdks (cyclin-dependent kinase),
but its exact mechanism of action remained poorly understood
until recently. Cks1 was found to be an essential cofactor for
efficient Skp2-dependent ubiquitination of p27Kip1. The critical
role of Cks1 in targeting p27Kip1 for efficient degradation by
Skp2 was emphasized by demonstrating the lack of p27Kip1
ubiquitination and breakdown in the absence of Cks1 in vitro
and the slow proliferation and accumulation of p27Kip1 in Cks1
nullizyous mice in vivo [18,19]. Recent studies from our and
other laboratories have investigated the expression of Cks1
levels in different human cancers and its relation to Skp2 and
p27Kip1 expression [20-24]. For example, we have shown that
in colorectal cancer the expression of Cks1 protein levels cor-
related strongly with the expression of Skp2 protein levels and
inversely with those of p27Kip1  [23]. Furthermore, Cks1
expression was increased in poorly differentiated tumors and
was strongly and independently associated with poor overall
survival [24]. The role of Cks1 in breast cancer, however, is
unknown.
In the present study, we investigated the expression of Cks1
in relation to Skp2 and p27Kip1 and prognosis in breast cancer.
We show that Cks1 expression is strongly associated with
Skp2 expression and inversely associated with p27Kip1 expres-
sion. Furthermore, our results suggest that Cks1 expression
may be used as an independent prognostic marker for dis-
ease-free and overall survival in breast cancer.
Materials and methods
Patients and tissue samples
Tissue samples from 50 patients with primary breast carcino-
mas that had been operated on more than 6 years before the
beginning of the study were collected for immunohistochemi-
cal studies, after we had obtained the approval of the institu-
tion's Human Investigation Committee. Patients presenting
with metastatic disease were excluded from this study. Clinical
and histological data were available for all of these patients.
Long-term follow-up data were provided by patients' medical
records and the Israel Cancer Registry.
Cell cultures
Human breast cancer cell lines (MCF-7, T47D, and MDA-MB-
231) were generously provided by Dr H Degani (Weizmann
Institute of Science, Rehovot, Israel). Because Skp2 levels
change during the cell cycle (being normally highest in the S
phase and lowest in the G1 phase) we cultured the cells in dif-
ferent media under conditions of similar proliferation rate in all
cell lines. MDA-MB-231 cells were grown in RPMI medium
(Biological Industries, Beth Ha'emek, Israel) supplemented
with 10% fetal calf serum, 100 Units penicillin, and 100 µg
streptomycin per ml and 1 mM sodium pyruvate. MCF-7 breast
carcinoma cells were cultured in Dulbecco's modified Eagle's
medium (DMEM; Biological Industries) supplemented with
10% fetal bovine serum, 4.5 g/l glucose, antibiotics as
described above, and 4 mM glutamine. The T47D cell line was
cultured in RPMI medium supplemented with 10% fetal calf
serum, 100 Units/ml penicillin, 100 µg/ml streptomycin, and
10 µg/ml insulin. All cell lines were cultured at 37°C in 5%
CO2. Under these conditions, the proliferation rate of all cell
lines was similar (21 to 22 hours doubling time).
Immunoblotting
Samples containing 30 µg of protein were resolved by electro-
phoresis on a 12.5% SDS-polyacrylamide gel and were trans-
ferred to nitrocellulose membranes. The membranes were
probed with affinity-purified rabbit polyclonal antibody
directed against a 12-amino-acid synthetic peptide from the
extreme C terminus of human Cks1 (gift of Dr A Hershko,
Technion, Haifa, Israel). This antibody does not cross-react
with Cks2. The antibody was diluted 1:200 in TBST (Tris-buff-
ered saline and 0.1% Tween 20) containing 10% (w/v) nonfat
dry milk. Membranes were also probed against the mouse
monoclonal antibody directed against Skp2 (Zymed Laborato-
ries Inc, South San Francisco, CA, USA) diluted 1:500, or with
a rabbit polyclonal antibody directed against p27Kip1 (Zymed)
diluted at 1:250. Membranes were also probed with a mouse
monoclonal antibody directed against Skp1 (Transduction
Laboratories, Lexington, KY, USA; 1:1000 dilution). Since lev-
els of Skp1 do not change in the cell cycle, this protein served
as an internal control to normalize for loading of cellular pro-
tein. After being washed with TBST, the immunoreactive pro-
teins were visualized with horseradish-conjugated IgG (Pierce,
Rockford, IL, USA) diluted 1:10,000 and an enhanced chemi-
luminescence system (SuperSignal West Pico; Pierce). All
immunoblot analyses were done at least twice.
Immunohistochemistry
Immunohistochemical studies were performed on formalin-
fixed tissue sections embedded in paraffin wax. Five-micron
sections were deparaffinized with xylene and rehydrated in a
series of ethanols.Available online http://breast-cancer-research.com/content/7/5/R737
R739
For epitope retrieval, slides were heated in 1 mM ethylenedi-
aminetetraacetic acid buffer (pH 8), either in a microwave oven
at 92°C for 20 min (p27Kip1) or in an Antigen Retrieval Proces-
sor (Milestone Inc, Sorsiole, Italy) at 120°C for 8 min (Skp2
and Cks1). After they had cooled, the slides were washed in
distilled water.
Skp2 staining was carried out in the NexES IHC Immunos-
tainer (Ventana Medical Systems, Tucson, AZ, USA), in
accordance with the manufacturer's instructions, using a mon-
oclonal antibody (Zymed) diluted 1:100.
Slides for p27Kip1and Cks1 staining were treated for 10 min
with 3% H2O2 in methanol to block endogenous peroxidase
and for 30 min with 10% nonimmune rabbit serum to block
nonspecific protein binding. The slides were then washed in
water and soaked in washing buffer (pH 7.4, Optimax; Bio-
genex, San Ramon, CA, USA) for 5 min. For p27Kip1 staining,
slides were incubated overnight at 4°C with the monoclonal
p27Kip1 antibody diluted 1:500. Staining was completed with
a Histostain-plus kit (Zymed) in accordance with the manufac-
turer's instructions. For Cks1 staining, slides were incubated
with an affinity-purified rabbit polyclonal antibody directed
against a 12-amino-acid synthetic peptide from the extreme C
terminus of human Cks1 (described above) diluted 1:40 for 2
hours at room temperature. Staining was completed using a
Super-sensitive Multilink Immunodetection kit (Biogenex) in
accordance with the manufacturer's instructions. The color
reaction product was developed with aminoethyl carbazole
(AEC). All sections were counterstained with hematoxylin.
For negative controls, slide sections that were positive for
staining were treated with 10% nonimmune rabbit serum
(Zymed) instead of the primary antibody. No staining was
observed in any of these controls.
The immunohistochemical slides were scored according to
the percentage of tumor cells exhibiting nuclear staining. To
define high and low protein expression, we used a cutoff of
50% p27Kip1 and 10% for Skp2, which is the cutoff used in
most previous studies [14,15]. The cutoff for Cks1 was 10%,
similar to the level used for Skp2, as in previous studies. When
stained, cells displayed similar intensities of nuclear staining
regardless of the percentage of cells stained, and therefore
the intensity of staining was not included in the score. The spe-
cificity of immunohistochemistry staining procedures for Skp2,
Cks1, and p27Kip1 was previously verified by comparing the
protein levels as determined by immunohistochemistry with
the protein levels determined by immunoblot analysis from the
same tumor specimens [15,23].
Statistical analysis
Statistical data analyses were performed using SPSS 11.0
statistical software package (SPSS Inc, Chicago, IL, USA).
First, the relations between Skp2, Cks1, and p27Kip1 and
those between protein levels and various clinical and patho-
logical features were studied using cross tabulation and Pear-
son's χ 2. Survival curves were constructed using the Kaplan–
Meier method and multivariate analysis by Cox regression; P
values less than 0.05 were considered significant.
Results
Cks1 protein expression is directly related to Skp2 
expression and inversely related to p27Kip1 expression in 
human breast cancer
We studied the expression of Cks1, Skp2, and p27Kip1 by
immunohistochemistry in 50 tumor samples obtained from
patients with breast cancer. The quality of immunostaining was
good, with minimal background reactivity. Cks1 levels were
very low or absent in all normal breast tissues adjacent to
tumors. However, Cks1 levels were not uniformly high in all
tumor specimens, being very high in some but virtually absent
in others (Table 1). Given the important biochemical link
between Cks1, Skp2, and p27Kip1, we examined the correla-
tion between these proteins. Regression analysis of all 50
cases showed an inverse correlation between Skp2 and
p27Kip1 levels (r = -0.395; P = 0.005). Cks1 expression was
strongly related to Skp2 expression (r = 0.477; P = 0.001)
and inversely related to p27Kip1 levels (r = -0.726; P < 0.001).
Thus, strong relations were found between the expressions of
all three proteins in 74% of the patients. High levels of Cks1
and Skp2 with low levels of p27Kip1 were observed in 15
patients, and low levels of Cks1 and Skp2 with high levels of
p27Kip1 were observed in 22 patients. A typical representative
immunohistochemical sample is shown in Fig. 1. In this tumor
sample, cancer cells show strong nuclear staining for Cks1
and Skp2 and weak staining for p27Kip1, but high p27Kip1 stain-
ing and low Cks1 and Skp2 staining in the normal surrounding
breast tissue. In 13 of the 50 cases, the above relation was not
found. In eight cases an inverse relation was found between
Cks1 and p27Kip1  expression but not between Skp2 and
p27Kip1 expression; in three cases, levels of both p27Kip1 and
Skp2 were high whereas Cks1 expression was low; and in
another five cases, p27Kip1 levels were low despite high Cks1
levels and low Skp2 levels. In another five cases, the differ-
ences between the three proteins were not significant.
Cks1 overexpression is associated with poor tumor 
differentiation, young age, and negative ER/PR status
To examine the relation between Cks1 expression and com-
mon parameters associated with aggressive tumor behavior,
we compared Cks1 levels with various clinicopathological fea-
tures such as age, tumor size, pathological grade, lymph node
status, and ER and PR expression (Table 1). A significant
direct correlation was found between high Cks1 levels and
loss of tumor differentiation (r = -0.421; P = 0.012), negative
ER expression (r  = -0.356; P = 0.013), and negative PR
expression (r = -0.404; P = 0.006). We also found a strong
relation between Cks1 overexpression and patient age less
than than 50 years (r = 0.327; P = 0.049), but did not observeBreast Cancer Research    Vol 7 No 5    Slotky et al.
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a significant correlation between Cks1 levels and lymph node
status (r = 0.029; P = 0.508) or tumor size (r = 0.192; P =
0.333).
Examination of the association between Skp2 or p27Kip1 and
patients' clinicopathological characteristics showed a strong
association between Skp2 expression and loss of tumor differ-
entiation (r = -0.400; P = 0.005), young age (r = -0.337; P =
0.022), and negative ER or negative PR status (r = -0.589; P
= 0.001 and r = -0.674; P = 0.001), respectively. Loss of
p27Kip1 was associated with loss of tumor differentiation (r = -
0.323; P = 0.032) and, respectively, loss of ER and PR (r =
0.298, P = 0.048; r = -0.316, P = 0.030 (Table 1)).
Because of the strong association between Cks1, Skp2, and
p27Kip1 levels and the ER status of the tumors, we next exam-
ined the expression of these proteins in estrogen-dependent
(MCF-7 and T47D) and estrogen-independent (MDA-MB-
231) breast carcinoma cell lines, and the possible effects of
estrogen modulation on the regulation of Skp2 and Cks1
expression. Basal levels of Cks1 and Skp2 were higher in
estrogen-independent cells than in estrogen-dependent cells,
whereas p27Kip1  levels were lower (Fig. 2a). Interestingly,
between the two estrogen-dependent cell lines, levels of Cks1
and Skp2 were higher in T47D cells, which phenotypicallly
have poorer cellular differentiation (Fig. 2b). Treatment of
T47D cells with estradiol increased Cks1 and Skp2 levels,
whereas treatment with tamoxifen down regulated Cks1 and
Skp2, resulting in an upregulation of p27Kip1 levels (Fig. 2b).
Cks1 overexpression is associated with poor disease-
free and overall survival in human breast cancer
To determine the association between Cks1 expression and
prognosis, we plotted Kaplan–Meier curves for disease-free
survival and overall survival. Complete 80-month follow-up
data were available for all the patients. Patients presenting
with high tumor Cks1 levels had significantly shorter disease-
free survival rates than patients with low Cks1 levels (54
Table 1
Relations between proteina expression and clinicopathological characteristics in patients with breast cancer
Characteristic Cks1 Skp2 p27Kip1
High Low Pb High Low Pb High Low Pb
Grade
1 2 8 0.012 2 8 0.005 2 8 0.032
2 14 14 0.012 7 21 0.005 14 14 0.032
3 10 2 0.012 9 3 0.005 8 4 0.032
Tumor sizec
T1 15 18 0.333 10 23 0.265 19 14 0.485
T2 10 6 0.333 7 9 0.265 8 8 0.485
T3 1 0 0.333 1 0 0.265 0 1 0.485
Lymph node involvementc
N0 16 15 0.508 11 20 0.803 18 13 0.387
N1 6 3 0.508 4 5 0.803 3 6 0.387
N2 4 6 0.508 3 7 0.803 6 4 0.387
Estrogen receptor expression
Negative 17 6 0.013 16 7 0.001 9 14 0.048
Positive 10 17 0.013 3 24 0.001 17 10 0.048
Progesterone receptor expression
Negative 15 3 0.006 14 4 0.001 5 13 0.032
Positive 12 20 0.006 4 27 0.001 20 12 0.032
Age (years)
>50 14 5 0.017 12 7 0.002 7 12 0.051
< 50 12 19 0.017 25 6 0.002 20 11 0.051
aCks1, cyclin kinase subunit 1; p27Kip1, a cell-cycle inhibitory protein; Skp2, S-phase kinase protein 2. bRefers to the differences between protein 
expression and the variables. cAccording to the TNM (tumor, node, metastases) staging system of the American Joint Committee on Cancer. P ≤  
0.05 (values shown in bold type) was considered statistically significant.Available online http://breast-cancer-research.com/content/7/5/R737
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months vs 76 months, respectively; P = 0.0007; Fig. 3a).
There was only one case of disease recurrence in patients with
low Cks1 levels, whereas in patients with high Cks1 levels,
disease recurrence was observed in 11 (42% of patients).
Similarly, Skp2 and p27Kip1 were also good predictors for dis-
ease-free survival (P = 0.0014 and P = 0.0191, respectively;
data not shown).
We also examined the prognostic role of Cks1 in predicting
local or distant relapse disease-free survival (Fig. 3b,c, respec-
tively). Patients with high Cks1 levels had both higher local
recurrence rates (P = 0.0352) and more distant relapse rates
(P = 0.0006) than patients with low Cks1 levels. Skp2 was
also found to be a good predictor for local (P = 0.0051) and
distal (P = 0.003) relapse rates, while p27Kip1 expression was
a predictor for distant relapse (P = 0.031) but not for local
recurrence (P = 0.136).
There was also a strong association between Cks1 expression
and overall survival (Fig. 4a). The mean survival rate for
Figure 1
Representative immunohistochemistry slides for Cks1, Skp2, and  p27Kip1 staining in breast cancer Representative immunohistochemistry slides for Cks1, Skp2, and 
p27Kip1 staining in breast cancer. Tumor cells of a grade II invasive duct 
cancer exhibiting strong and diffuse nuclear staining for Skp2 (S-phase 
kinase protein 2) and Cks1 (cyclin kinase subunit 1) (× 300) and low 
p27Kip1 staining. Note the inversely low Skp2 and Cks1 staining with 
high p27Kip1 staining of normal adjacent breast tissue (× 400).
Figure 2
Immunoblots showing Cks1, Skp2, and p27Kip1 proteins in breast can- cer cell lines Immunoblots showing Cks1, Skp2, and p27Kip1 proteins in breast can-
cer cell lines. (a) Levels of the three proteins Cks1 (cyclin kinase subu-
nit 1), Skp2 (S-phase kinase protein 2), and p27Kip1 were measured in 
MDA-MB-231 (an estrogen-independent cell line) and MCF-7 (an 
estrogen-dependent cell line). Skp1 levels were determined to confirm 
equal protein loading. (b)Effect of estrogen modulation on Cks1, Skp2, 
and p27Kip1 expression in T47D cells (an estrogen-dependent breast 
cancer cell line) treated with estradiol (0.5 µM) or tamoxifen (10 µM). 
P27, p27Kip1.Breast Cancer Research    Vol 7 No 5    Slotky et al.
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patients with low Cks1 expression was 79 months, signifi-
cantly higher than that (72 months) of patients with high Cks1
levels (P = 0.0415). Similarly, Skp2 expression was also found
to be a strong predictor of overall survival (69 months vs 79
months P = 0.0224) (Fig. 4b), but p27Kip1 expression was not
(P = 0.0831; Fig. 4c).
Discussion
Recent studies have clearly shown that Cks1 plays an essen-
tial role in Skp2-mediated degradation of p27Kip1. The mecha-
Figure 3
The association between Cks1 expression and disease-free survival The association between Cks1 expression and disease-free survival. 
The expression of Cks1 (cyclin kinase subunit 1) was plotted in relation 
to overall (a), local (b), or distant (c) recurrence rates. Analyses were 
constructed using the Kaplan–Meier method. Protein expression was 
considered low if fewer than 10% of cell nuclei were stained and high if 
more than 10% of nuclei were stained.
Figure 4
The association between expression of cell cycle proteins and survival  of patients with breast cancer The association between expression of cell cycle proteins and survival 
of patients with breast cancer. Relation between Cks1 (cyclin kinase 
subunit 1)(a), Skp2 (S-phase kinase protein 2) (b), and p27Kip1 (c) 
expression and overall survival (death). Analyses were constructed 
using the Kaplan–Meier method. Protein expression was considered 
low if fewer than 10% of cell nuclei were stained and high if more than 
10% of nuclei were stained.Available online http://breast-cancer-research.com/content/7/5/R737
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nistic model that emerges from these studies suggests that
Cks1 is associated with Skp2 and confers an allosteric
change in Skp2 that increases its affinity for phosphorylated
p27Kip1 [18]. As a result, the Cks1-Skp2 interaction enables
efficient transfer of ubiquitin to p27Kip1, resulting in rapid pro-
teasome-mediated degradation. Whereas the role of Skp2 as
an oncogene responsible for down regulation of p27Kip1 pro-
tein levels has been well established in a wide variety of can-
cers, the role of Cks1 in many of these cancers, and in
particular breast cancer, is unknown. This study provides new
insights into its role in human breast cancer. Using immunohis-
tochemical studies obtained from tumor specimens of patients
with nonmetastatic breast cancer, we found that Cks1 was
overexpressed in subsets of patients with unfavorable histo-
logical features. Furthermore, its expression was strongly and
independently associated with poor disease-free survival and
poor overall survival. Similar findings were recently reported by
our and other laboratories in aggressive gastric, lung, oral, and
colorectal carcinomas [20-24]. Taken together, these results
suggest that Cks1 has an important role in the decrease in
p27Kip1 levels in aggressive cancers.
The interaction between the three proteins was evident in a
significant proportion of the study patients, whereby the
expression of Cks1 was strongly associated with Skp2
expression and inversely with p27Kip1protein levels. However,
in five patients high Cks1 levels were associated with low
p27Kip1 despite low Skp2 levels, and in three patients Cks1
levels were high but Skp2 and p27Kip1 levels were low. These
findings, in which the inverse relation between Cks1 and
p27Kip1 was stronger than that between Skp2 and p27Kip1 lev-
els, are particularly interesting, considering that Skp2 is the
prime mediator of p27Kip1 degradation. Although we do not yet
know the reason for this observation, we postulate that in the
presence of high Cks1 levels Skp2 degradation of p27Kip1 is
more efficient and that lower levels of Skp2 are therefore
required to down-regulate p27Kip1.
Cks1 overexpression was also strongly associated with vari-
ous clinical and pathological features that are commonly used
to determine aggressive tumor behavior, including poor tumor
differentiation and lack of receptors to estrogen and proges-
terone. The association between Cks1, Skp2, and p27Kip1 and
ER expression was also observed in breast carcinoma cell
lines. Estrogen-dependent cell lines displayed lower levels of
Cks1 and Skp2 than estrogen-independent cell lines. Never-
theless, estrogen modulation affected the levels of these pro-
teins, suggesting that tamoxifen may have an important
therapeutic role in ER-positive cancers expressing high levels
of Cks1 or Skp2.
We found a strong correlation between young age of the
patient and overexpression of either Cks1 or Skp2. Thus,
these results support the notion that breast cancer has more
aggressive tumor biology in young patients than in older ones,
and that this difference may account, at least in part, for the
poorer survival rates of younger patients than of older patients
with similar clinicopathological features. Overall, Cks1 or
Skp2 were each found to be good prognostic markers for dis-
ease-free and overall survival. Interestingly, there was no sig-
nificant association between p27Kip1 expression and overall
survival (P = 0.083). A possible reason for this finding is the
relatively small number of patients in this study. Larger studies
may be required to resolve this issue.
Conclusion
The results of the present study provide additional insights into
the importance of alterations in cell-cycle regulatory proteins
and tumor progression in breast cancer. Our findings suggest
that Cks1 has an important role in the deregulation of the cell-
cycle protein p27Kip1 in breast cancer. Overexpression of
Cks1 was strongly associated with increased Skp2 expres-
sion and down regulation of p27Kip1 levels, resulting in aggres-
sive tumor behavior and poor prognosis. Thus, both Cks1 and
Skp2 may be considered as potential novel prognostic mark-
ers and targets for the future development of specific thera-
peutic interventions in breast cancer.
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